Cargando…
Real-World Characterization of Dimethyl Fumarate-Related Gastrointestinal Events in Multiple Sclerosis: Management Strategies to Improve Persistence on Treatment and Patient Outcomes
INTRODUCTION: Delayed-release dimethyl fumarate (DMF) is an effective treatment for multiple sclerosis (MS). Some patients experience gastrointestinal (GI) adverse events (AEs) that may lead to premature DMF discontinuation. This study characterized the impact of site-specific GI management strategi...
Autores principales: | Min, Jinny, Cohan, Stanley, Alvarez, Enrique, Sloane, Jacob, Phillips, J. Theodore, van der Walt, Anneke, Koulinska, Irene, Fang, Fang, Miller, Catherine, Chan, Andrew |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6534646/ https://www.ncbi.nlm.nih.gov/pubmed/30706431 http://dx.doi.org/10.1007/s40120-019-0127-2 |
Ejemplares similares
-
Effectiveness of Dimethyl Fumarate in Patients With Relapsing Multiple Sclerosis Switching After Suboptimal Response to Glatiramer Acetate, Including Patients With Early Multiple Sclerosis: Subgroup Analysis of RESPOND
por: Repovic, Pavle, et al.
Publicado: (2020) -
Real-world effectiveness of dimethyl fumarate versus fingolimod in a
cohort of patients with multiple sclerosis using standardized, quantitative
outcome metrics
por: Hersh, Carrie M, et al.
Publicado: (2022) -
Effect of dimethyl fumarate on lymphocyte subsets in patients with relapsing multiple sclerosis
por: Buckle, Guy, et al.
Publicado: (2020) -
Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2018) -
Real-World Safety and Effectiveness of Dimethyl Fumarate in Black or African American Patients with Multiple Sclerosis: 3-Year Results from ESTEEM
por: Williams, Mitzi J., et al.
Publicado: (2020)